227.99
price down icon0.11%   -0.26
 
loading
Precedente Chiudi:
$228.25
Aprire:
$228.78
Volume 24 ore:
3.53M
Relative Volume:
0.66
Capitalizzazione di mercato:
$402.76B
Reddito:
$58.33B
Utile/perdita netta:
$3.73B
Rapporto P/E:
108.50
EPS:
2.1013
Flusso di cassa netto:
$18.24B
1 W Prestazione:
-0.69%
1M Prestazione:
+3.64%
6M Prestazione:
+26.40%
1 anno Prestazione:
+20.22%
Intervallo 1D:
Value
$226.25
$229.04
Intervallo di 1 settimana:
Value
$223.10
$232.81
Portata 52W:
Value
$163.81
$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name
Nome
Abbvie Inc
Name
Telefono
(847) 932-7900
Name
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Dipendente
55,000
Name
Cinguettio
@abbvie
Name
Prossima data di guadagno
2025-04-25
Name
Ultimi documenti SEC
Name
ABBV's Discussions on Twitter

Confronta ABBV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.99 403.22B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
LLY
Lilly Eli Co
825.45 736.03B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
190.40 463.72B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.36 254.84B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.49 217.76B 63.43B 16.42B 14.72B 6.4861

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-14 Downgrade Erste Group Buy → Hold
2025-10-01 Downgrade HSBC Securities Buy → Hold
2025-09-17 Aggiornamento Berenberg Hold → Buy
2025-08-12 Ripresa Piper Sandler Overweight
2025-08-07 Aggiornamento Daiwa Securities Neutral → Outperform
2025-05-14 Downgrade Citigroup Buy → Neutral
2025-04-22 Iniziato Cantor Fitzgerald Overweight
2024-12-10 Ripresa BofA Securities Neutral
2024-12-05 Downgrade Daiwa Securities Outperform → Neutral
2024-11-22 Aggiornamento Leerink Partners Market Perform → Outperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-04 Aggiornamento Argus Hold → Buy
2024-10-17 Iniziato Bernstein Mkt Perform
2024-06-05 Aggiornamento HSBC Securities Hold → Buy
2024-05-17 Iniziato Cantor Fitzgerald Overweight
2024-01-29 Aggiornamento William Blair Mkt Perform → Outperform
2023-12-18 Downgrade HSBC Securities Buy → Hold
2023-12-11 Aggiornamento Goldman Neutral → Buy
2023-11-09 Iniziato Deutsche Bank Hold
2023-10-30 Aggiornamento Barclays Equal Weight → Overweight
2023-10-20 Ripresa UBS Neutral
2023-09-29 Iniziato Raymond James Outperform
2023-07-25 Iniziato William Blair Mkt Perform
2023-07-14 Iniziato HSBC Securities Buy
2023-04-05 Downgrade Argus Buy → Hold
2023-03-01 Iniziato Guggenheim Buy
2023-02-22 Downgrade Wolfe Research Outperform → Peer Perform
2023-02-10 Aggiornamento SVB Securities Underperform → Market Perform
2022-11-18 Iniziato Credit Suisse Outperform
2022-11-08 Downgrade Societe Generale Buy → Hold
2022-08-01 Downgrade Atlantic Equities Overweight → Neutral
2022-05-23 Iniziato SVB Leerink Underperform
2022-05-06 Downgrade Daiwa Securities Outperform → Neutral
2022-04-06 Ripresa Morgan Stanley Overweight
2022-02-28 Downgrade UBS Buy → Neutral
2022-02-03 Reiterato BMO Capital Markets Outperform
2022-02-03 Reiterato Barclays Equal Weight
2022-02-03 Reiterato BofA Securities Neutral
2022-02-03 Reiterato Goldman Neutral
2022-01-13 Iniziato Redburn Buy
2022-01-12 Reiterato BMO Capital Markets Outperform
2021-12-09 Ripresa Wells Fargo Overweight
2021-11-23 Aggiornamento Societe Generale Hold → Buy
2021-07-27 Ripresa Truist Buy
2021-04-07 Ripresa RBC Capital Mkts Outperform
2020-11-10 Ripresa Bernstein Outperform
2020-09-29 Iniziato Berenberg Hold
2020-06-23 Aggiornamento Atlantic Equities Neutral → Overweight
2020-06-09 Aggiornamento Wolfe Research Peer Perform → Outperform
2020-06-02 Aggiornamento Argus Hold → Buy
2020-05-18 Ripresa BofA/Merrill Neutral
2020-05-12 Aggiornamento JP Morgan Neutral → Overweight
2020-05-11 Ripresa Morgan Stanley Overweight
2020-04-20 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-02-06 Iniziato Mizuho Buy
2020-01-07 Iniziato RBC Capital Mkts Sector Perform
2019-12-26 Reiterato Cowen Outperform
2019-09-26 Aggiornamento Citigroup Neutral → Buy
2019-08-20 Aggiornamento Piper Jaffray Neutral → Overweight
2019-06-27 Aggiornamento Wolfe Research Underperform → Peer Perform
2019-06-26 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-05-28 Iniziato Goldman Neutral
2019-04-29 Aggiornamento BMO Capital Markets Underperform → Market Perform
Mostra tutto

Abbvie Inc Borsa (ABBV) Ultime notizie

pulisher
Oct 25, 2025

How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance

Oct 25, 2025
pulisher
Oct 25, 2025

Why AbbVie Inc. (4AB) stock stays on top picksWeekly Trade Report & Weekly Breakout Watchlists - newser.com

Oct 25, 2025
pulisher
Oct 25, 2025

AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com

Oct 25, 2025
pulisher
Oct 24, 2025

Published on: 2025-10-24 20:28:34 - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment? - TipRanks

Oct 24, 2025
pulisher
Oct 24, 2025

Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - sharewise.com

Oct 24, 2025
pulisher
Oct 24, 2025

Is AbbVie Inc. stock a buy on dipsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com

Oct 24, 2025
pulisher
Oct 23, 2025

AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - The Motley Fool

Oct 23, 2025
pulisher
Oct 23, 2025

Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

Can AbbVie Inc. stock attract analyst upgradesMarket Risk Report & Reliable Price Breakout Signals - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Will AbbVie Inc. stock attract more institutional investors2025 Retail Activity & Stepwise Trade Signal Implementation - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Insider Monkey

Oct 22, 2025
pulisher
Oct 22, 2025

AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey

Oct 22, 2025
pulisher
Oct 22, 2025

AbbVie Up More Than 30% in 6 Months: How to Play the Stock - The Globe and Mail

Oct 22, 2025
pulisher
Oct 22, 2025

YieldBoost AbbVie From 2.9% To 6.9% Using Options - Nasdaq

Oct 22, 2025
pulisher
Oct 22, 2025

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades' - Benzinga

Oct 22, 2025
pulisher
Oct 21, 2025

How sentiment analysis helps forecast AbbVie Inc.Global Markets & Community Trade Idea Sharing Platform - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Can AbbVie Inc. stock withstand economic slowdownBull Run & Technical Pattern Based Signals - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Measuring AbbVie Inc.’s beta against major indices2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

How AbbVie Inc. (4AB) stock performs in volatility spikesJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will AbbVie Inc. stock outperform Dow JonesInsider Selling & Stepwise Trade Execution Plans - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Why AbbVie Inc. stock is in analyst buy zoneQuarterly Trade Summary & Daily Entry Point Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Can AbbVie Inc. stock surprise markets with earningsTrade Signal Summary & Daily Momentum Trading Reports - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

AbbVie's Rinvoq Beats Humira in Key Arthritis Trial - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Fund Update: Bank Pictet & Cie (Europe) AG added 112,421 shares of ABBVIE (ABBV) to their portfolio - Quiver Quantitative

Oct 21, 2025
pulisher
Oct 21, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Alpha Cognition Inc (ACOG) and Exelixis (EXEL) - The Globe and Mail

Oct 21, 2025
pulisher
Oct 21, 2025

Bernstein Remains a Hold on AbbVie (ABBV) - The Globe and Mail

Oct 21, 2025
pulisher
Oct 21, 2025

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients - AbbVie News Center

Oct 21, 2025
pulisher
Oct 21, 2025

How AbbVie Inc. stock compares with tech leadersQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Five things for pharma marketers to know for Tuesday, October 21, 2025 - Medical Marketing and Media

Oct 21, 2025
pulisher
Oct 21, 2025

Will AbbVie Inc. stock maintain strong growthRate Cut & High Conviction Buy Zone Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

How AbbVie Inc. stock performs in rising dollar environment2025 Year in Review & Fast Gain Stock Trading Tips - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 2025Weekly Loss Report & Risk Adjusted Swing Trade Ideas - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Lobbying Update: $980,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative

Oct 20, 2025
pulisher
Oct 20, 2025

Is AbbVie Inc. a candidate for recovery play2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

AbbVie's Rinvoq (ABBV) Outperforms Humira in Key Rheumatoid Arthritis Trial - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

AbbVie's Rinvoq beats Humira in head-to-head rheumatoid arthritis trial - Seeking Alpha

Oct 20, 2025
pulisher
Oct 20, 2025

AbbVie's Rinvoq shows superiority over Humira in head-to-head arthritis study - Reuters

Oct 20, 2025
pulisher
Oct 20, 2025

How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressure2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings - sharewise.com

Oct 20, 2025
pulisher
Oct 20, 2025

Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com

Oct 20, 2025
pulisher
Oct 20, 2025

Guggenheim Raises Price Target for AbbVie (ABBV) to $242 | ABBV Stock News - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

AbbVie (ABBV) Reports Positive Phase 3b/4 Study Results for Upad - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

AbbVie Says Upadacitinib Shows Superior Efficacy Over Humira in Late-Stage Rheumatoid Arthritis Trial - MarketScreener

Oct 20, 2025

Abbvie Inc Azioni (ABBV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general JNJ
$190.40
price down icon 1.08%
drug_manufacturers_general NVS
$130.36
price down icon 0.97%
drug_manufacturers_general MRK
$87.49
price up icon 0.36%
drug_manufacturers_general NVO
$52.96
price down icon 0.51%
$291.76
price down icon 0.39%
Capitalizzazione:     |  Volume (24 ore):